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This review proposes that lipopolysaccharide (LPS, found in the wall of all Gram-negative
bacteria) could play a role in causing sporadic Alzheimer’s disease (AD). This is based
in part upon recent studies showing that: Gram-negative E. coli bacteria can form
extracellular amyloid; bacterial-encoded 16S rRNA is present in all human brains with
over 70% being Gram-negative bacteria; ultrastructural analyses have shown microbes
in erythrocytes of AD patients; blood LPS levels in AD patients are 3-fold the levels in
control; LPS combined with focal cerebral ischemia and hypoxia produced amyloid-like
plaques and myelin injury in adult rat cortex. Moreover, Gram-negative bacterial LPS was
found in aging control and AD brains, though LPS levels were much higher in AD brains.
In addition, LPS co-localized with amyloid plaques, peri-vascular amyloid, neurons, and
oligodendrocytes in AD brains. Based upon the postulate LPS caused oligodendrocyte
injury, degraded Myelin Basic Protein (dMBP) levels were found to be much higher in AD
compared to control brains. Immunofluorescence showed that the dMBP co-localized
with β amyloid (Aβ) and LPS in amyloid plaques in AD brain, and dMBP and other
myelin molecules were found in the walls of vesicles in periventricular White Matter
(WM). These data led to the hypothesis that LPS acts on leukocyte and microglial TLR4-
CD14/TLR2 receptors to produce NFkB mediated increases of cytokines which increase
Aβ levels, damage oligodendrocytes and produce myelin injury found in AD brain. Since
Aβ1–42 is also an agonist for TLR4 receptors, this could produce a vicious cycle that
accounts for the relentless progression of AD. Thus, LPS, the TLR4 receptor complex,
and Gram-negative bacteria might be treatment or prevention targets for sporadic AD.
Keywords: Alzheimer’s disease, lipopolysaccharide, cytokines, TLR4, myelin, MBP, oligodendrocytes, amyloid
plaque
INTRODUCTION
Rare early-onset familial forms of Alzheimer’s disease (AD) are associated with autosomal
dominant mutations in the amyloid beta precursor protein (AβPP), presenilin 1 and presenilin
2 genes (Goate and Hardy, 2012). Mouse models based upon these mutated human genes have
guided much of the drug discovery for AD (Belkacemi and Ramassamy, 2012; Hall and Roberson,
2012). However, clinical trials based upon these models have yet to lead to successful treatments
(Selkoe, 2011; Huang and Mucke, 2012; Cavanaugh et al., 2014). This has raised questions about
the ‘‘amyloid hypothesis’’ for sporadic AD (Herrup, 2015).
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An enigma in the AD field has been the inability to
identify a cause(s) for the much more common sporadic
late onset alzheimer’s disease (LOAD/AD). This is important
because neither β amyloid (Aβ) nor abnormal tau may ‘‘cause’’
sporadic AD, but rather could be downstream of an unrelated
primary pathological process. In the first part of this brief
review some epidemiological and neuropathological findings
that do not appear to have a direct connection with the
amyloid hypothesis are summarized. In the second portion of
the review, data are summarized showing Lipopolysaccharide
(LPS) in human brain and greater amounts of LPS in AD
brain that are associated with amyloid plaques, perivascular
amyloid and neurons. In the third portion, recent studies
showing the presence of myelin injury in all AD compared
to control brains are reviewed, and the association of LPS
with oligodendrocytes which could injure oligodendrocytes and
myelin. In the final fourth portion of the review a simple
model is presented by which LPS acts on TLR4/CD14 receptors
to activate NFkB and increase cytokines which contribute
to increasing Aβ in AD brain and producing myelin injury
including formation of degraded Myelin Basic Protein (dMBP).
Since LPS and Aβ are both agonists for the TLR4/CD14 receptor
(Lehnardt et al., 2002; Vollmar et al., 2010; Scott et al.,
2017), this could set up a vicious cycle where LPS acts
on the TLR4/CD14 receptor which increases Aβ which in
turn provides positive feedback on the TLR4/CD14 receptor
to produce progressive injury in AD brain. TLR4-TLR2
downstream interactions are not discussed to limit the scope of
the review.
EPIDEMIOLOGICAL AND BIOLOGICAL
FACTORS IN AD
Inflammation
Inflammation has repeatedly been implicated in AD but the
source for this inflammation has been elusive. Inflammatory
proteins in blood, notably C reactive protein (CRP) and IL6,
are elevated several years before the clinical onset of dementia
in several studies (Schmidt et al., 2002; Engelhart et al., 2004;
Tilvis et al., 2004; Kuo et al., 2005). A high plasma CRP has been
associated with a 3-fold increased risk of developing AD years
later (Schmidt et al., 2002). Another study showed cognitively
intact older individuals in the top tertile for leukocyte IL1β or
TNFα production have∼3 times increased risk of developing AD
compared to those in the lowest tertile (Tan et al., 2007). Though
clinical trials have shown non-steroidal anti-inflammatory drugs
(NSAIDs) do not affect cognitive decline in AD (de Craen et al.,
2005; Imbimbo, 2009; Imbimbo et al., 2010), meta-analyses show
regular NSAID use is associated with a 2 fold reduction in
the odds of developing AD (McGeer et al., 1996). Moreover,
a large case control study (>200,000 subjects) showed that
the regular use of NSAIDs reduced the risk of developing
AD (Vlad et al., 2008). Thus, NSAIDS may delay the onset
of AD, but once it develops NSAIDS do not appear to affect
the course of AD, suggesting an opportunity for intervention
prior to disease onset (Grammas, 2011; Butchart and Holmes,
2012). These data suggest that inflammation is occurring for
some time prior to onset of AD pathology and symptoms, but
there has been little indication of what drives the inflammation
that goes on for years. This review proposes this may be due
to Gram-negative bacterial LPS in blood and in brain of AD
subjects.
Infection
Delirium, which is often caused by infection, is associated with
increased incidence of subsequent development of dementia in
cognitively intact old individuals (Rahkonen et al., 2000a,b).
The presence of one or more infections over a 5-year
follow up period increased the odds of developing AD, and
risk increased with age (Dunn et al., 2005). Receiving DPT
vaccines early in life as well as other vaccines later in
life significantly reduces the risk of subsequent AD (Tyas
et al., 2001; Verreault et al., 2001). Protection by DPT
vaccine may be due in part to preventing infection by the
Gram-negative Bordetella Pertussis bacterium which causes
whooping cough. Tooth loss (Stein et al., 2007) and oral
infections (Poole et al., 2013; Abbayya et al., 2015; Chen
et al., 2017) have been associated with AD. Furthermore,
Porphyromonas gingivalis (Ishida et al., 2017) and LPS from
Porphyromonas gingivalis (Wu et al., 2017) produce AD-like
phenotypes in mice. In addition, Spirochetes (Miklossy, 1993;
Miklossy et al., 1994, 2004; Riviere et al., 2002), chlamydophila
pneumonia (Hammond et al., 2010), Helicobacter pylori
(Kountouras et al., 2009), fungi (Pisa et al., 2015), herpes
viruses (Civitelli et al., 2015) and cytomegalovirus (Lovheim
et al., 2018) are also reported to be involved in with AD
pathology. Interestingly, previous in vitro studies demonstrate
that amyloid-like morphological changes occur following
Borrelia burgdorferi spirochetes or LPS exposure. These studies
suggest that ADmight be a neurological disorder associated with
infectious agents.
It is possible that several different infections might initiate
downstream AD pathology. The possibility of infection received
a significant boost with the recent discovery that every
human brain examined had evidence of Gram-negative bacteria
(Branton et al., 2013; Emery et al., 2017) though the issue of
contamination in these studies has yet to be resolved. For this
review the focus is on Gram-negative bacterial LPS as it is
associated with and may cause AD pathology.
Neurovascular Abnormalities in AD
There is considerable evidence for vascular abnormalities in
AD. Cerebral blood flow is reduced in AD prior to cognitive
decline (Ruitenberg et al., 2005). Patients with an APOE4 allele
have disrupted fMRI connectivity (blood flow correlations) in
the absence of amyloid plaques (detected by PET) or decreased
CSF Aβ42 (Sheline et al., 2010). Cerebral glucose metabolism is
decreased in preclinical and prodromal AD before symptoms
(Hunt et al., 2007; Herholz, 2010). Microvessels isolated from
AD patients release many cytokines, chemokines and proteases
compared to control patients (Grammas, 2011). In genetic
mouse models of AD, alterations of blood flow and BBB
permeability occur before symptoms and before amyloid beta
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deposition (Iadecola et al., 1999; Ujiie et al., 2003; Iadecola,
2004). Using vascular corrosion casts, the 3D arrangement of
the brain vessels is abnormal in a mouse model of AD prior
to appearance of amyloid plaques (Meyer et al., 2008). In
addition, BBB breakdown has been demonstrated in humans
with mild cognitive impairment (MCI) and early AD before
brain atrophy and dementia (Montagne et al., 2017). These
data provide strong evidence for neurovascular abnormalities
in sporadic AD in humans and in mouse genetic AD models
prior to appearance of brain amyloid plaque neuropathology
(Zlokovic, 2005, 2008, 2011) and support the fact that both
cardiovascular disease and cerebrovascular disease are significant
risk factors for sporadic AD (Tyas et al., 2001; Veurink et al.,
2003; White et al., 2005; Zhu et al., 2007; Marlatt et al., 2008;
de la Torre, 2009; Guglielmotto et al., 2009). Notably, cerebral
vascular disease and AD pathology co-exist in up to 80% of aging
human brains (Schneider et al., 2007; Savva et al., 2009; Iadecola,
2013). These data are relevant for our finding of LPS in brain
described below, since areas of ischemic and/or hypoxic injury
might provide a portal for LPS entry from blood into human
brain.
Recent neuroimaging studies in individuals with MCI and
early AD have shown BBB breakdown in the hippocampus
(Montagne et al., 2015) and several GrayMatter (GM) andWhite
Matter (WM) regions (van de Haar et al., 2016a,b, 2017).
Genetic Variants
Besides the original discovery of the association of
Apolipoprotein E4 with sporadic AD (Bertram et al., 2010;
Bertram and Tanzi, 2012; Goate and Hardy, 2012), additional
genetic insights into sporadic AD have been made using GWAS
(Bertram et al., 2010; Bertram and Tanzi, 2012). The genes
implicated in these studies are involved in Aβ clearance at
the blood brain barrier (APOE, BIN1, CLU, CR1, PICALM;
Zlokovic et al., 1996; O’Brien and Wong, 2011; Wu et al.,
2012), in inflammation in blood and brain (APOE, CD33,
CLU, CR1, HLA-DRB5/1, INPP5D, TREM2; Bertram et al.,
2010; Veerhuis, 2011; Bertram and Tanzi, 2012; Crehan et al.,
2012), in the immune response (CR1, CD33, MS4A, CLU,
ABCA7, EPHA1, HLA-DRB5-HLA-DRB1), endocytosis (BIN1,
PICALM, CD2AP, EPHA1 and SORL1) and lipid biology
(CLU, ABCA7 and SORL1; Karch and Goate, 2015). Many of
these genes are expressed by peripheral monocytes and brain
microglia (Villegas-Llerena et al., 2016) and could be associated
with an infectious cause of sporadic AD (Heneka et al., 2015).
Our model of how LPS could lead to AD neuropathology
could incorporate all these genes and molecules (see below).
Since Aβ also acts on TLR4 receptors on both monocytes and
neutrophils, this could help explain how neutrophils promote
AD-like pathology with cognitive decline via the leukocyte
LFA-1 adhesion molecule in two AD mouse models (Zenaro
et al., 2015).
Myelin Injury in AD Brain
Myelin injury has been recognized in AD brain for some time,
including the very first report of AD pathology by Alzheimer
(Alzheimer et al., 1991; Scheltens et al., 1995; Englund, 1998;
Möller and Graeber, 1998; Bartzokis, 2011). The relationship of
the myelin injury to the other better-known neuropathology of
AD, including amyloid plaques and tau-neurofibrillary tangles,
has been unclear and the explanation for such myelin injury
has been equally obscure. However, recently myelin injury has
been suggested as an important/principal component of AD
pathophysiology. The volume of White Matter Hyperintensities
(WMH) in AD brain predicts the rate and severity of cognitive
decline (Brickman et al., 2008). The Low-density lipoprotein
receptor-related protein 1, which transports Aβ out of brain,
is also an essential receptor for myelin phagocytosis providing
a link between myelin damage and Aβ (Gaultier et al., 2009).
Moreover, Aβ1–42 inhibits myelin sheet formation in vitro
(Horiuchi et al., 2012). Aβ1–42 directly binds myelin basic
protein (MBP; Liao et al., 2009, 2010; Kotarba et al., 2013).
There is a focal loss of oligodendrocytes and myelin within
and adjacent to amyloid plaques in familial and sporadic AD
brain (Mitew et al., 2010). However, the absence of MBP
decreases the accumulation of Aβ1–42 in transgenic AD mice,
and essentially eliminate amyloid plaques (Ou-Yang and Van
Nostrand, 2013). More recently it has been discovered that loss of
ceramide synthase 2 activity, necessary for myelin biosynthesis,
precedes tau and amyloid pathology in human AD cortex
(Couttas et al., 2016). In addition, oligodendrocyte and myelin
injury can precede the formation of amyloid plaques and tau
pathology in a mouse AD model (Mitew et al., 2010; Hall and
Roberson, 2012). Clinically, WMH are more highly associated
with preclinical AD than imaging and cognitive markers of
neurodegeneration; and WMH are now considered a core
feature of dominantly inherited AD (Desai et al., 2010; Kandel
et al., 2016; Lee et al., 2016). Of interest, there are very high
titers of autoantibodies against a variety of myelin proteins
in blood of AD patients compared to controls (Papuc et al.,
2015). The cause of the myelin injury in AD brain, however,
remains to be elucidated. This review hypothesizes that Gram
negative bacterial LPS molecules are present in AD WM and
GM where they bind oligodendrocytes and cause an increase
in cytokines and oxidative stress that contributes directly to
damage of oligodendrocytes and to myelin proteins including
MBP which then associate with Aβ1–42 in amyloid plaques in AD
brain.
Microbiome of the Gut and AD
There is emerging evidence that the gut microbiome affects
neurological diseases including AD. There is a different gut
microbiome in wild type mice compared to mouse AD
models (Shen et al., 2017) and in control compared to
AD patients (Vogt et al., 2017). There is an association of
brain amyloidosis with pro-inflammatory gut bacterial taxa
and peripheral inflammation markers in cognitively impaired
elderly humans (Cattaneo et al., 2017). As people age they
have more Gram-negative bacteria in the gut. Antibiotic-
induced perturbations in gut microbial diversity influences
neuro-inflammation and amyloidosis in a murine model
of AD (Minter et al., 2016). Serum IgG antibody levels
to periodontal microbiota, some derived from the gut, are
associated with incident AD (Noble et al., 2014). The gut
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microbiome is implicated in normal neurodevelopment, autism
spectrum disorders, schizophrenia, depression, Parkinson’s,
multiple sclerosis, stroke and aging (Branton et al., 2016;
Sampson et al., 2016; Sharon et al., 2016; Winek et al., 2016).
Though there is a marked increase in reports on the gut
microbiome affecting neuropsychiatric diseases, very few have
developed a cogent hypothesis on how this occurs. This proposal
hypothesizes that Gram-negative bacteria, potentially from the
gut or gums as well as from systemic infections, all release LPS
which is engulfed via TLR4-CD14 receptors by blood leukocytes
including monocytes and neutrophils, and by brain microglia.
The TLR4 mediated activation of NFkB increases cytokines
which contribute to myelin damage. Studies have demonstrated
that NFkB pathway regulates the activity of Beta-secretase 1
(BACE1; Buggia-Prevot et al., 2008; Guglielmotto et al., 2012),
the crucial enzyme for Aβ production and the BACE1 level
in AD brain is increased compared to control (Guglielmotto
et al., 2012). These studies suggest that activation of NFkB may
contribute to increases of Aβ and amyloid pathology in AD
brain.
LPS IN HUMAN AD BRAIN
Based upon the above considerations, and based upon
genomic studies of blood of AD patients showing evidence
of inflammation, oxidative stress and hypoxia (Bai et al., 2014),
the hypothesis was developed that several systemic factors act
together to produce AD (Zhan et al., 2015a). There must be
some cause of inflammation, it was reasoned that either an
infectious agent or molecules from infectious agents might be
important in causing AD, in particular lipopolysaccharide (LPS)
which is found in the outer wall of all Gram-negative bacteria.
This was done for several reasons. (1) LPS containing E. coli
bacteria can form extracellular amyloid (Blanco et al., 2012;
Hill and Lukiw, 2015). (2) A recent study showed bacterially-
encoded 16S rRNA sequences in all human brain specimens
with Gram-negative, LPS containing alpha-proteobacteria
representing over 70% of the bacterial sequences (Branton
et al., 2013). (3) Ultrastructural analysis by scanning electron
microscopy confirmed the presence of microbes in erythrocytes
of AD patients (Bester et al., 2015; Potgieter et al., 2015).
(4) Another study demonstrated that blood LPS levels in AD
patients are 3-fold the levels in control (Zhang et al., 2009). (5) In
addition, we developed a rat model where LPS was combined
with focal cerebral ischemia and hypoxia (LPS-IS-HY; Zhan
et al., 2015a). This combination was chosen because it causes
myelin injury in newborn rodent brain (Hagberg et al., 2002;
Lehnardt et al., 2002, 2003; Pang et al., 2003) and evidence of
WM injury is found in every human AD brain (Zhan et al.,
2014, 2015b). The combination of LPS, focal ischemia and
hypoxia in adult rats produced: (a) increases of cytokines in
brain; (b) myelin injury in the ischemic and non-ischemic
hemispheres; and (c) formation of amyloid-like plaques where
degraded MBP, AβPP and Aβ co-localized. These data led to
the search for LPS and Gram-negative bacteria in human AD
brain.
Gram-negative bacteria are one of the most important
causes of human infectious diseases including gastroenteritis
(Escherichia coli, Shigella, Salmonella, Vibrio cholera),
pulmonary infections (Klebsiella pneumoniae, Legionella,
Pertussis/whooping cough, Pseudomonas aeruginosa),
urinary tract infections (Escherichia coli, Proteus mirabilis,
Enterobacter cloacae, Serratia marcescens, Bacteroides),
ulcers (Helicobacter pylori), sexually transmitted disease
(Neisseria gonorrhoeae), meningitis (Neisseria meningitidis)
and gum/periodontal disease (Porphyromonas gingivalis).
Gram-negative bacteria are also resident in the normal gut
and increase in numbers with age (Sharon et al., 2016).
Gram-negative bacterial periodontal disease has been
repeatedly associated with AD (Noble et al., 2014; Kamer
et al., 2015; Olsen and Singhrao, 2015). The evidence that
blood LPS levels in AD patients are 3-fold the levels in
control (Zhang et al., 2009) also suggests that LPS associates
with AD.
Based upon the above literature and the rat model findings,
a search for LPS and other E. coli molecules in human AD
and control brains was undertaken. Studying LPS is problematic
since it is so pervasive in the environment, and is a common
contaminant of solutions in the laboratory. Thus, the studies
were performed with endotoxin free reagents, and multiple
controls performed to ensure no LPS contamination of the
reagents used. Western blots were performed for LPS and
FIGURE 1 | Western Blot analysis of Gram-negative bacterial molecules in
human brain. (A) Western blots for E. coli K99 pili protein showed K99 protein
in 3/3 Alzheimer’s disease (AD) White Matter (WM) samples, 2/3 AD Gray
Matter (GM) samples and 0/3 Control GM samples. β-actin was used as
loading control. (B) Western blots for Gram-negative bacteria
lipopolysaccharide (LPS) in 3/3 AD WM samples, 3/3 AD GM samples and
0/3 Control GM samples. β-actin was used as loading control. This Figure is
from Zhan et al. (2016). Reproduced with permission.
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FIGURE 2 | The antibody to LPS stains LPS in human brain on Western blots and using immunofluorescence, and immunofluorescence can be eliminated by
immunoprecipitating the antibody with excess LPS. Left Panel: the antibody to LPS stains one large band on a Western blot (AD (−) lane) which is eliminated when
the antibody was immunoprecipitated with excess E. coli J5 LPS (AD (+) lane). The band at 150 kD in both lanes shows equal protein loading in the two lanes. Right
Panel: The antibody to LPS produced more immunofluorescence in AD cortex (B) compared to control cortex (A). After immunodepletion, the immunofluorescence
in AD (D) and Control (C) cortex were eliminated. These are supplementary figures from Zhan et al. (2016). Reproduced with permission.
the K99 pili protein derived from E. coli (Zhan et al., 2016).
Figure 1A shows the presence of E. coli K99 pili protein in
two of three AD superior temporal GM samples, and in three
of three AD frontal lobe WM samples and none detectable in
three control GM samples. Figure 1B shows LPS in the same
three AD GM and three AD WM samples compared to none
detectable by Western blot in the three control GM samples
(Zhan et al., 2016). In Figure 2 the Western blots (on the left)
show LPS stained from AD brain (−) and elimination of the
LPS band using immunodepletion with excess LPS (AD (+)). The
stained band at ∼150 kD shows equal protein loading in the two
lanes.
To localize LPS at the cellular level immunolabeling
was performed using the same antibody as used for the
Western blots. There was LPS immunofluorescence in control
(Figure 2A) and in AD brain (Figure 2B), but with LPS+
aggregates only observed in AD brain (Figures 2A,B).
Immunofluorescence with the antibody to LPS, but
immunodepleted with LPS, showed no fluorescent staining
in control (Figure 2C) or AD brain (Figure 2D). These
findings were important for showing LPS aggregates in AD
brains. The lack of staining on Western blots for LPS in
control brains (Figure 1B, left panels) is likely accounted
for by the lower sensitivity of Western blots compared to
immunofluorescence.
The relationship of LPS to amyloid plaques was examined
next. LPS co-localized with Aβ in AD brain (Figure 3) and
LPS co-localized with perivascular amyloid in AD brain (not
shown). There were several different patterns of co-localization
of LPS and Aβ1–40/42 in AD brains from more LPS compared
to Aβ1–40/42 (Figure 3A) to more Aβ1–40/42 compared to LPS
(Figure 3B) in the amyloid plaques. Not shown in the figures here
was the finding of LPS in the nucleus of neurons in AD brains
(Zhan et al., 2016).
FIGURE 3 | Co-localization of LPS and Aβ in human AD brain. (A) There were
large clusters of LPS that co-localized with Aβ1–40/42 in some amyloid plaques.
(B) The most common pattern, however were confluent Aβ1–40/42 stained
plaques that had LPS stained particles (yellow on merged image) within them.
(A,B) are from Zhan et al. (2016). Reproduced with permission.
In addition to superior temporal GM and frontal lobe WM of
AD brains, the same LPS antigen is found in the hippocampus of
AD brains as well (Zhao et al., 2017a,b). Moreover, one previous
study demonstrated that LPS from Porphyromonas gingivalis is
present in some AD brains as well (Poole et al., 2013). Thus, it is
possible that LPS frommultiple strains of Gram negative bacteria
might be involved in AD pathology.
DEGRADED MBP (dMBP) IN AD
COMPARED TO CONTROL BRAINS
dMBP Increased in AD Brain
The combination of LPS-IS-HY demonstrated evidence of
myelin injury in the adult rat brain (Zhan et al., 2015a). Thus, a
search for evidence of myelin injury in AD compared to control
brains was undertaken, and determined if LPS was associated
with the myelin injury in AD brain.
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FIGURE 4 | Assessing myelin amounts and myelin damage in AD and control brains. (A) Western blots for intact Myelin Basic Protein (MBP) and degraded Myelin
Basic Protein (dMBP) show more dMBP in AD compared to control brains. Actin served as a lane loading control. (B) Quantification of the bands showed more MBP
in AD compared to controls brains, more dMBP in AD compared to control brains, and a greater dMBP/MBP ratio in AD compared to control brains (∗p < 0.05;
∗∗∗p < 0.001). This Figure is from Zhan et al. (2015b). Reproduced with permission.
FIGURE 5 | LPS co-localizes with MAG stained oligodendrocytes. There were
more LPS stained cells in AD cortex compared to Control Cortex (A1,B1).
There were more MAG stained oligodendrocytes in in AD cortex compared to
Control cortex (A2,B2). Merging of images for LPS and MAG showed that
LPS co-localized with MAG stained oligodendrocytes, and there were more
LPS-MAG stained oligodendrocytes in AD cortex compared to control
(A3,B3). This is a supplementary figure from Zhan et al. (2016). Reproduced
with permission.
MBP and dMBP levels were examined in 13 AD brains
and 10 control brains (Figure 4; Zhan et al., 2015b). dMBP
was found in every AD brain, but not in every control aging
brains (Figure 4A). Quantification showed more MBP in AD
compared to control brains (Figure 4B), and much more dMBP
in AD compared to control brains (Figure 4B). Indeed, the
ratio of dMBP/MBP was greater in AD compared to control
brains (Figure 4B; Zhan et al., 2015b). The antibody to dMBP
stains a protein at 37 kDa which is higher in molecular weight
compared to intact MBP. It was postulated that the antibody
to dMBP probably detects some fragment of MBP (degraded
MBP/dMBP) which complexes with other molecule(s) (Zhan
et al., 2015b).
The next studies determined whether LPS co-localized with
MAG (myelin associated glycoprotein) stained oligodendrocytes
in cortex (Figure 5; Zhan et al., 2016). There appeared to
be more MAG stained oligodendrocytes in AD (Figure 5B2)
compared to control cortex (Figure 5A2). There were more
LPS stained cells in AD (Figure 5B1) compared to control
(Figure 5A1) cortex.Most LPS stained cells in cortex co-localized
with MAG stained oligodendrocytes (Figures 5A3,B3), with
more LPS/MAG stained oligodendrocytes in AD (Figure 5B3)
compared to control cortex (Figure 5A3; Zhan et al., 2016).
These data show more oligodendrocytes in AD brain compared
to control and could explain higher MBP levels in AD brain
(Figure 4B). In addition, since LPS co-localizes with MAG
stained oligodendrocytes, this suggests LPS could damage
oligodendrocytes leading to increased dMBP seen in AD brain
(Figure 4B). LPS acts on the TLR4 receptor to activate NFkB
which increases cytokines that can damage oligodendrocytes
and damage myelin proteins (Pang et al., 2003, 2010; Deng
et al., 2008, 2014; Paintlia et al., 2008). Not shown here is an
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FIGURE 6 | Myelin proteins in amyloid plaques of AD brains. FSB stained amyloid plaques (A1,B1) showed Myelin Basic Protein (MBP) around the plaques (A2,A3),
and Neurofilament (NF) protein around the plaques (B2,B3). FSB did not co-localize with MBP (A3) or with NF (B3). In contrast, dMBP formed aggregates (C2)
similar in size to Aβ1–42 aggregates (C1), with Aβ1–42 and dMBP being co-localized (C3). FSB is (E, E)-1-fluoro-2, 5-bis (3-hydroxycarbonyl-4-hydroxy) styrylbenzene
which is a Congo red derivative. Bar = 25 µm. (D) Immunoprecipitation of cortex with an antibody to dMBP followed by Western blotting for AβPP showed two
bands in AD and control cortex, with greater amounts in the 4 AD subjects compared to the 4 Control subjects. (E) Quantification of the immunoprecipitation studies
in (D) showed greater intensity of the upper and lower bands in the AD cortex compared to Control cortex (∗P < 0.05; ∗∗∗P < 0.001). This Figure is from Zhan et al.
(2015b). Reproduced with permission.
increased number of oligodendrocyte progenitor cells (OPCs)
in AD compared to control brain (Zhan et al., 2016). The data
suggests that LPS injures oligodendrocytes and myelin proteins
including dMBP and MAG, and that this leads to proliferation
of OPCs that differentiate into mature oligodendrocytes (Zhan
et al., 2016).
With evidence of consistent myelin injury in AD brain,
the localization of dMBP in AD brain was examined.
Neither MBP (Figure 6A2) nor neurofilament protein (NF;
Figure 6B2) co-localized with FSB ((E, E)-1-fluoro-2, 5-bis
(3-hydroxycarbonyl-4-hydroxy) styrylbenzene, Figures 6A1,B1)
stained amyloid plaques in AD brain (Figures 6A3,B3).
However, Aβ1–42 (Figure 6C1) did co-localize with dMBP
(Figure 6C2) in amyloid plaques in AD brain (Figure 6C3;
Zhan et al., 2015b). These data were supported by biochemical
findings suggesting dMBP directly bound AβPP and Aβ1–42
(Zhan et al., 2015b). Figure 6D shows that immunoprecipitation
with an antibody to dMBP followed by Western blotting with
an antibody to AβPP showed bands in AD and control brain
(Figure 6D), but with greater levels in AD brain (Figure 6E;
Zhan et al., 2015b). These data support the idea that LPS injures
FIGURE 7 | Localization of dMBP in AD brain in periventricular white matter
(PVWM) and in the perivascular space of white matter (PVSR). The WM
galactocerebroside (GALC) (A1,B1) co-localized with dMBP (A2,B2) in the
PVWM (A3) and in PVSR (B3). The immunofluorescence occurred in vesicles
throughout the PVWM and PVSR. This Figure is from Zhan et al. (2014).
Reproduced with permission.
oligodendrocytes with the resultant dMBP binding to and being
co-localized with Aβ within amyloid plaques in AD brain.
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FIGURE 8 | Proposed model of how LPS, in combination with other factors, might produce amyloid plaques, myelin injury and Tau hyperphosphorylation. In
addition, the model includes a possible mechanism by which autosomal dominant mutations in AβPP and Presenilin could damage myelin via Aβ actions on
TLR4/CD14 receptors to increase cytokines.
FIGURE 9 | Myelin basic protein (MBP) colocalizes with FSB ((E, E)-1-fluoro-2,
5-bis (3-hydroxycarbonyl-4-hydroxy) styrylbenzene) stained amyloid plaques in
cortex of 5XFAD mice. MBP stained aggregates in cortex of 8-month-old (A)
and 10-month-old (B) 5XFAD mice co-localized with FSB stained amyloid
plaques. Bar = 50 µm. This Figure is from Zhan et al. (2015a). Reproduced
with permission.
The distribution of dMBP in WM of AD brain was also
examined (Figure 7; Zhan et al., 2014). Using an antibody
to galactocerebroside (GALC) as a marker for myelin, many
GALC stained walls of vesicles in periventricular WM (PVWM;
Figure 7A1) and the perivascular space (Figure 7B1) of
AD brains were found (Zhan et al., 2014). These GALC
stained vesicles were shown to co-localize with dMBP in both
periventricular WM (Figures 7A2,A3) and in the perivascular
space (Figures 7B2,B3) of AD brains. There were fewer vesicles
in control brains in the periventricular WM (not shown). The
above results show consistent myelin injury in both AD gray and
WM (Zhan et al., 2015b).
PROPOSED MODEL OF LPS INDUCED
INJURY IN AD BRAIN
A tentative model of injury is shown in Figure 8 where LPS binds
to TLR4/CD14 receptors on peripheral monocytes/macrophages,
neutrophils and on brain microglia. TLR4/CD14 activation by
LPS leads to NFκB mediated induction of cytokines including
IL1, IL6 and TNF in monocytes/neutrophils in blood and from
microglia in brain. Since LPS does not enter normal brain when
given alone (Banks and Erickson, 2010; Banks et al., 2015), it
is likely that other factors contribute to LPS entry into aging
brain including ischemia, hypoxia, peripheral cytokines and
other factors. Impaired blood brain barrier (BBB) and areas
devoid of BBB might aid entry of LPS to the brain. Once
LPS entered brain it would bind to TLR4/CD14 receptors on
microglia which would activate NFκB mediated increases of
intracerebral cytokines. Very high levels of cytokines produce
myelin injury (see below). LPS induction of cytokines can also
increase accumulation of AβPP and Aβ, which in turn can
act on TLR4 to create a positive feedback loop to increase
Aβ (Wu et al., 2015). LPS also acts on the BBB to decrease
Aβ exit from brain (Banks et al., 2015; Figure 8). Aggregation
of Aβ, AβPP, degraded myelin proteins (including dMBP)
and LPS contributes to formation of amyloid plaques (see
below; Figure 8). Finally, LPS is known to induce tau hyper
phosphorylation (Kitazawa et al., 2005; Lee et al., 2010; Liu et al.,
2016; Figure 8).
Role of LPS
Gram-negative E. coli bacteria can synthesize extracellular
amyloid (Zhao and Lukiw, 2015). This may be relevant since
a recent RNAseq study demonstrated bacterial molecules in
human brain, and showed the majority were associated with
Gram-negative, LPS containing alpha Proteobacteria (Branton
et al., 2013). Thus, the LPS found in AD brain could be
derived frommolecules of Gram-negative bacteria entering brain
from the blood, from Gram-negative bacteria entering brain, or
possibly from endogenous Gram-negative bacteria in brain.
LPS binds the TLR4/CD14 complex on peripheral
monocytes/macrophages or brain microglia to activate NFκB
and increase production of cytokines including IL1, IL6 and TNF
(Ikeda et al., 1999; Rossol et al., 2011; Enkhbaatar et al., 2015).
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LPS down regulation of ADAM10 and upregulation of BACE-
1/PS-1 may partially explain LPS induced increases β-AβPP
and Aβ (Sheng et al., 2003; Zhao et al., 2014; Wu et al., 2015).
LPS also increases Aβ levels in brain by acting at the blood
brain barrier and impairing LRP which is responsible for Aβ
efflux from brain (Erickson et al., 2012; Banks et al., 2015). LPS
at high doses can damage the BBB (Banks et al., 2015) which
could facilitate entry of LPS itself into brain. Alternatively,
monocytes/macrophages may carry LPS into brain. LPS binding
to TLR4 on endothelial cells also leads to cytokine release (Verma
et al., 2006). LPS binds serum amyloid P and Aβ (de Haas et al.,
2000), it binds MBP (Raziuddin and Morrison, 1981) and LPS
promotes tau hyper phosphorylation (Kitazawa et al., 2005; Lee
et al., 2010; Liu et al., 2016). Thus, LPS could contribute to all
of the key neuropathological findings in AD brain including:
amyloid plaques, myelin injury and tau hyperphosphorylation
(Figure 8).
Role of TLR4/CD14 Complex
Polymorphisms in TLR4 and CD14 have been associated with
AD in some studies (Balistreri et al., 2008; Rodríguez-Rodríguez
et al., 2008; Chen et al., 2012) and whole genome studies
have implicated TLR4 in AD (Li et al., 2015). TLR4 levels
are increased in AβPP transgenic AD mice and human
AD brain and treatment of microglia with amyloid peptide
increases IL6 and TNF in microglia and kills microglia via
the TLR4 receptor (Walter et al., 2007). The microglial
TLR4 receptor is required for recruitment of leukocytes into
brain in response to intracranial injections of LPS (Zhou et al.,
2006). CD14 binds amyloid peptide fibrils (Fassbender et al.,
2004) and is a microglial receptor for phagocytosis of Aβ
(Liu et al., 2005). Deletion of CD14 attenuates pathology in
AD mice by decreasing inflammation (Reed-Geaghan et al.,
2010). In the neonatal LPS/hypoxia model, LPS mediates death
of oligodendrocytes via the TLR4 receptor (Lehnardt et al.,
2002); and, LPS activated microglia can kill OPCs (Pang et al.,
2010).
Role of Cytokines in Myelin Injury
LPS-TLR4-NFκB mediated increase of cytokines is proposed to
damage oligodendrocytes and myelin which leads to formation
of myelin aggregates (Figure 8). TLR4 mediated increases of IL1,
IL6 and TNF can kill mature oligodendrocytes, oligodendrocyte
progenitors and damage myelin (Fan et al., 2009; Xie et al.,
2016). Tumor necrosis factor alpha mediates lipopolysaccharide-
induced microglial toxicity to developing oligodendrocytes when
astrocytes are present (Selmaj and Raine, 1988; Li et al., 2008).
Other cytokines are also induced by TLR4 activation and these
might also play a role in injury.
Damaged Myelin Interacts with Aβ
MBP directly binds AβPP and Aβ and inhibits Aβ fibrillary
assembly via residues 54–64 in MBP (Liao et al., 2009, 2010;
Kotarba et al., 2013). Pure MBP degrades AβPP and Aβ
peptides, though degraded MBP lacking autolytic activity may
not degrade Aβ40 or Aβ42 (Liao et al., 2009). A knockout
mouse of MBP (bigenic Tg-5xFAD/MBP−/−) showed markedly
decreased numbers of amyloid plaques and decreased insoluble
Aβ (Ou-Yang and Van Nostrand, 2013). These findings suggest
degraded MBP (dMBP) might play a role in amyloid plaque
formation. Axonal/myelin injury results in formation of myelin
aggregates, and degraded MBP binds AβPP and Aβ peptides
(Liao et al., 2009, 2010; Kotarba et al., 2013), and along with
LPS and other molecules leads to the formation of amyloid
plaques.
Could the LPS Model Relate to Familial
AD?
Familial AD is due to mutations in AβPP, presenilin-1 and
presenilin-2, and these mutations result in an increase of
brain and blood Aβ. It is still debated whether soluble
or insoluble Aβ are important, and how they relate to
tau hyper phosphorylation. Several groups have proposed
that Aβ actions on the TLR4/CD14 complex could be
important in the pathogenesis of AD (Figure 8). Aβ binding
to TLR4/CD14 would increase cytokines which would
lead to further increases of Aβ and to myelin injury and
production of dMBP (Figure 8). This could help explain the
association of WMH/myelin injury with familial AD (Lee et al.,
2016).
To begin to address this, studies were done to determine
whether a mouse model of AD which contained 3 AβPP
mutations and 2 presenilin-1 mutations (5XFAD mouse)
had myelin aggregates associated with its amyloid plaques.
Indeed, at 8 months (Figure 9A) and 10 months of age
(Figure 9B) the 5XFAD mouse showed that MBP stained
myelin aggregates co-localized with FSB stained amyloid
plaques (Zhan et al., 2015a). Though it is not known how
the myelin is damaged, it is possible that Aβ activation of
TLR4 could lead to myelin injury as shown in Figure 8. That
is, both LPS and Aβ are ligands for TLR4/CD14 (Erridge,
2010) and thus both could contribute to myelin injury. This
conclusion supports recent imaging studies that found WMH
to be a core feature of autosomal dominant familial AD
(Lee et al., 2016). Thus, sporadic WMH could be a result
of the actions of LPS-TLR4 mediated injury and/or Aβ-
TLR4 mediated injury to myelin possibly in combination with
ischemia/hypoxia.
Caveats to the Proposed Model
Though the above discussion focuses on LPS, other
Gram-negative molecules are found in AD brain (Zhan et al.,
2016). The significance of these to AD pathogenesis is not clear,
but could be important. The source of LPS and other bacterial
molecules in brain is not clear, so that exogenous infections
vs. some source within the body or the brain must be resolved.
Since LPS is in AD brain, perhaps molecules from other classes
of infectious agents might also be relevant in subgroups of AD
cases that might be mediated via other Toll-like receptors.
CONCLUSION
It is hypothesized that LPS, in combination with other
factors, leads to amyloid plaques, myelin injury and tau
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hyperphosphorylation in AD brain. Since the presence of
LPS in human AD brain has been confirmed in different
laboratories, treatment and prevention targets for sporadic AD
could include LPS, TLR4/CD14 receptors, and Gram-negative
bacteria. A vaccine against LPS to prevent AD could be
considered if future studies continue to support a role of LPS
in AD.
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